Loading…
Government Shutdown Accountability and Economic Report Act of 2017
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Government Shutdown Accountability and Economic Report Act of 2017 This bill prohibits Members of Congress from being paid salaries during a pay period in which a government shutdown is in effect after the regularly scheduled general election for federal office held in November 2018. For the purpose of this bill, a government shutdown is considered to be in effect if there is a lapse in appropriations for any federal agency or department as a result of a failure to enact a regular appropriations bill or continuing resolution. If a government shutdown occurs during the 115th Congress, congressional salaries must be withheld during the shutdown and released to Members of Congress at the end of the Congress, subject to an exception for any day during the 115th Congress which occurs after the date of the regularly scheduled general election for federal office held in November 2018. During a government shutdown, the Congressional Budget Office must submit specified reports to Congress regarding the costs and economic effects of the shutdown.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2018 · fourth_quarter · Pharmacy
Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases, including raising awareness about saline and local anesthetic shortages. Oppose legislation that would harm the 340B Drug Discount Program for safety net hospitals and support legislation to prevents the implementation of the cuts in CMS Final 2017 OPPS Rule (CMS-2017-0091), the SERV Communities Act (support) (H.R. 6071) and H.R. 4392 (support). Support reforms aimed at creating more competition in the generic drug market, including ending pay for delay (S.124), and support other pro-competition policies, including legislation that would prohibit evergreening and abuse of citizen petitions, and promote the growth of biosimilars. Supported legislation to increase competition in the drug marketplace and prevent REMS abuses, the CREATES Act (S. 974/H.R.2214) (support). Raise awareness about generic injectable opioid shortages, urge engagement by the Food & Drug Administration Office of Drug Shortages and approval by the Drug Enforcement Agency of CII quota requests to increase production of injectable opioid products in short supply. Submitted comments to DEA urging the revision of its quota allocation process to recognize the unique institutional needs for injectable opioids. Submitted comments to DEA opposing proposed aggregate quota reductions for CY 2018 Schedule II controlled substances.
Referred to the Committee on House Administration, and in addition to the Committee on Oversight and Government Reform, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress.gov source codes: H11100, H11100-A
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $580,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), White House Office
2018 · third_quarter · Pharmacy
Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases, including raising awareness about saline and local anesthetic shortages. Oppose legislation that would harm the 340B Drug Discount Program for safety net hospitals and support legislation to prevents the implementation of the cuts in CMS Final 2017 OPPS Rule (CMS-2017-0091), the SERV Communities Act (support) (H.R. 6071) and H.R. 4392 (support). Support reforms aimed at creating more competition in the generic drug market, including ending pay for delay (S.124), and support other pro-competition policies, including legislation that would prohibit evergreening and abuse of citizen petitions, and promote the growth of biosimilars. Supported legislation to increase competition in the drug marketplace and prevent REMS abuses, the CREATES Act (S. 974/H.R.2214) (support). Raise awareness about generic injectable opioid shortages, urge engagement by the Food & Drug Administration Office of Drug Shortages and approval by the Drug Enforcement Agency of CII quota requests to increase production of injectable opioid products in short supply. Submitted comments to DEA urging the revision of its quota allocation process to recognize the unique institutional needs for injectable opioids. Submitted comments to DEA opposing proposed aggregate quota reductions for CY 2018 Schedule II controlled substances.
Client expense: $600,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), White House Office
2018 · second_quarter · Pharmacy
Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases, including raising awareness about saline shortages. Oppose legislation that would harm the 340B Drug Discount Program for safety net hospitals and support legislation to prevents the implementation of the cuts in CMS Final 2017 OPPS Rule (CMS-2017-0091), the SERV Communities Act (support) (H.R. 6071) and H.R. 4392 (support) Support reforms aimed at creating more competition in the generic drug market, including ending pay for delay (S.124) and prohibiting REMS abuses (S.944/H.R.2214), and support other pro-competition policies, including legislation that would prohibit evergreening and abuse of citizen petitions, and promote the growth of biosimilars. Raise awareness about injectable opioid shortages, urge engagement by the Food & Drug Administration Office of Drug Shortages and approval by the Drug Enforcement Agency of CII quota requests to increase production of injectable opioid products in short supply. Submitted comments to DEA urging the revision of its quota allocation process to recognize the unique institutional needs for injectable opioids. Supported legislation to increase competition in the drug marketplace, the CREATES Act (S. 974) (support)
Client expense: $610,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), White House Office
2018 · first_quarter · Pharmacy
Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases, including raising awareness about saline shortages. Oppose legislation that would harm the 340B drug discount program for safety net hospitals, and support legislation (H.R.4392) that prevents the implementation of 340B reductions finalized in the CMS outpatient rule (CMS-2017-0091). Support reforms aimed at creating more competition in the generic drug market, including ending pay for delay (S.124) and prohibiting REMS abuses (S.944/H.R.2214), and support other pro-competition policies, including legislation that would prohibit evergreening and abuse of citizen petitions, and promote the growth of biosimilars. Raise awareness about injectable opioid shortages, urge approval by the Drug Enforcement Agency of CII quota requests to increase production of injectable opioid products in short supply.
Client expense: $630,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), White House Office
2017 · fourth_quarter · Pharmacy
Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases, including raising awareness about saline shortages. Oppose legislation that would harm the 340B drug discount program for safety net hospitals, and support legislation (H.R.4392) that prevents the implementation of 340B reductions finalized in the CMS outpatient rule (CMS-2017-0091). Support reforms aimed at creating more competition in the generic drug market, including ending pay for delay (S.124) and prohibiting REMS abuses (S.944/H.R.2214), and support other pro-competition policies, including legislation that would prohibit evergreening and abuse of citizen petitions, and promote the growth of biosimilars.
Client expense: $640,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), White House Office
2017 · third_quarter · Pharmacy
Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases. Support drug pricing legislation that would promote competition by fast tracking generic drug applications (H.R. 749/S.297). Oppose legislation that would harm the 340B drug discount program for safety net hospitals. Support reforms aimed at creating more competition in the generic drug market, including ending pay for delay (S.124) and prohibiting REMS abuses (S.944/H.R.2214)
Client expense: $600,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), White House Office